Uncategorized
Wet AMD treatment AVA-101 meets safety endpoint
The subretinal gene therapy injection treatment for wet age-related macular edema AVA-101 met its 12-month primary endpoint based on ophthalmic and systemic safety in a phase 2a trial, according to a press release from Avalanche Biotechnologies.AVA-101 contains a gene encoding sFlt-1 anti-VEGF protein and AAV2 vector in a single subretinal injection intended to reduce the burden of repeated injection treatments, according to the release.